These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 29988078)

  • 41. Ethics and the FDA.
    Fielder J
    IEEE Eng Med Biol Mag; 2006; 25(4):13-7. PubMed ID: 16898653
    [No Abstract]   [Full Text] [Related]  

  • 42. Precision Medicines Have Faster Approvals Based On Fewer And Smaller Trials Than Other Medicines.
    Pregelj L; Hwang TJ; Hine DC; Siegel EB; Barnard RT; Darrow JJ; Kesselheim AS
    Health Aff (Millwood); 2018 May; 37(5):724-731. PubMed ID: 29733717
    [TBL] [Abstract][Full Text] [Related]  

  • 43. FDA Breakthrough Therapy Designation: Evaluating the Quality of the Evidence behind the Drug Approvals.
    Herink MC; Irwin AN; Zumach GM
    Pharmacotherapy; 2018 Sep; 38(9):967-980. PubMed ID: 30043413
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The Vioxx debacle.
    Fielder JH
    IEEE Eng Med Biol Mag; 2005; 24(2):106-9. PubMed ID: 15825852
    [No Abstract]   [Full Text] [Related]  

  • 45. The right to a trial: Should dying patients have access to experimental drugs?
    Groopman J
    New Yorker; 2006 Dec; ():40-7. PubMed ID: 17176539
    [No Abstract]   [Full Text] [Related]  

  • 46. Clinical Trial Evidence Supporting US Food and Drug Administration Approval of Novel Cancer Therapies Between 2000 and 2016.
    Ladanie A; Schmitt AM; Speich B; Naudet F; Agarwal A; Pereira TV; Sclafani F; Herbrand AK; Briel M; Martin-Liberal J; Schmid T; Ewald H; Ioannidis JPA; Bucher HC; Kasenda B; Hemkens LG
    JAMA Netw Open; 2020 Nov; 3(11):e2024406. PubMed ID: 33170262
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Sidelining safety--the FDA's inadequate response to the IOM.
    Smith SW
    N Engl J Med; 2007 Sep; 357(10):960-3. PubMed ID: 17804840
    [No Abstract]   [Full Text] [Related]  

  • 48. FDA science: from concept to consumer.
    Rados C
    FDA Consum; 2004; 38(3):10-1. PubMed ID: 15218837
    [No Abstract]   [Full Text] [Related]  

  • 49. Post-market drug safety evidence sources: an analysis of FDA drug safety communications.
    Ishiguro C; Hall M; Neyarapally GA; Dal Pan G
    Pharmacoepidemiol Drug Saf; 2012 Oct; 21(10):1134-6. PubMed ID: 23033257
    [No Abstract]   [Full Text] [Related]  

  • 50. 2015 FDA drug approvals.
    Mullard A
    Nat Rev Drug Discov; 2016 Feb; 15(2):73-6. PubMed ID: 26837582
    [No Abstract]   [Full Text] [Related]  

  • 51. NerveCenter: FDA requirements for generic drug applications.
    Ann Neurol; 2010 Sep; 68(3):A11. PubMed ID: 20818779
    [No Abstract]   [Full Text] [Related]  

  • 52. FDA vulnerability revealed.
    Nature; 2015 Aug; 524(7566):387. PubMed ID: 26310730
    [No Abstract]   [Full Text] [Related]  

  • 53. 2010 FDA drug approvals.
    Mullard A
    Nat Rev Drug Discov; 2011 Feb; 10(2):82-5. PubMed ID: 21283092
    [No Abstract]   [Full Text] [Related]  

  • 54. They are from the government and they really are here to help you.
    Woosley RL
    J Clin Pharmacol; 2008 Feb; 48(2):142-3. PubMed ID: 18199889
    [No Abstract]   [Full Text] [Related]  

  • 55. From Tissue-Agnostic to N-of-One Therapies: (R)Evolution of the Precision Paradigm.
    Adashek JJ; Subbiah V; Kurzrock R
    Trends Cancer; 2021 Jan; 7(1):15-28. PubMed ID: 33008795
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Priority drugs well represented among 1998 approvals. FDA says all performance goals were met.
    Miller JL
    Am J Health Syst Pharm; 1999 Mar; 56(5):408, 411-2. PubMed ID: 10096697
    [No Abstract]   [Full Text] [Related]  

  • 57. Treatment recommendations to cancer patients in the context of FDA guidance for next generation sequencing.
    Dy GK; Nesline MK; Papanicolau-Sengos A; DePietro P; LeVea CM; Early A; Chen H; Grand'Maison A; Boland P; Ernstoff MS; Edge S; Akers S; Opyrchal M; Chatta G; Odunsi K; Pabla S; Conroy JM; Glenn ST; DeFedericis HT; Burgher B; Andreas J; Giamo V; Qin M; Wang Y; Kanehira K; Lenzo FL; Frederick P; Lele S; Galluzzi L; Kuvshinoff B; Morrison C
    BMC Med Inform Decis Mak; 2019 Jan; 19(1):14. PubMed ID: 30658646
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Gaps, tensions, and conflicts in the FDA approval process: implications for clinical practice.
    Deyo RA
    J Am Board Fam Pract; 2004; 17(2):142-9. PubMed ID: 15082674
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Flexibility in the FDA approach to orphan drug development.
    Hunter NL; Rao GR; Sherman RE
    Nat Rev Drug Discov; 2017 Nov; 16(11):737-738. PubMed ID: 28860647
    [No Abstract]   [Full Text] [Related]  

  • 60. Precision medicine and oncology: an overview of the opportunities presented by next-generation sequencing and big data and the challenges posed to conventional drug development and regulatory approval pathways.
    Doherty M; Metcalfe T; Guardino E; Peters E; Ramage L
    Ann Oncol; 2016 Aug; 27(8):1644-6. PubMed ID: 27117532
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.